Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled enoxaparin with or without inhaled N-acetylcysteine for SARS-CoV-2/COVID-19
ACTRN12621000704897Phase 2Terminated
- Sponsor
- Atossa Therapeutics
- Start
- Sep 2021
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of enoxaparin and acetylcysteine in coronavirus disease 2019 (COVID-19) (8 arms), sponsored by Atossa Therapeutics. Primary endpoints: Safety and tolerability of inhaled enoxaparin in healthy volunteers, Safety and tolerability of inhaled enoxaparin plus inhaled N-acetylcysteine in healthy volunteers and 1 more. Started Sep 2021; status: terminated.
02
Drugs
enoxaparinacetylcysteine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ACTRN12621000704897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000704897.